Publications by authors named "Yingbing Sang"

Background And Aims: Bullous pemphigoid is an autoimmune blistering disease that affects the elderly mostly. First-line treatment of systemic corticosteroids may cause significant adverse effects, especially in patients with multiple co-morbidities. Dupilumab shows certain effectiveness in treating BP.

View Article and Find Full Text PDF

Prophylactic application of emollients has been an effective strategy against infant atopic dermatitis (AD); however, the difference of different emollients is unknown. We performed this network meta-analysis to compare different emollients in preventing infant AD. A systematic search was performed in PubMed, EMBASE and Cochrane library to identify relevant studies from their inception through 28 February, 2022.

View Article and Find Full Text PDF

In response to the accumulation of genetic mutations and cellular changes, ultraviolet radiation B (UVB) skin lesions undergo dysplasia and transform into a cutaneous squamous cell carcinoma (CSCC). Consistent with our previous findings that secreted frizzled-related protein 1 (SFRP1), a member of the SFRP gene family, was downregulated in human CSCC tissue samples, we found a significant downregulation of SFRP1 in HaCaT, A431, and SCL-1 cells after UVB irradiation. DNA methyltransferase 1 (DNMT1) was significantly increased in CSCC tissues as well as UVB-exposed A431 and SCL-1 cells.

View Article and Find Full Text PDF
Article Synopsis
  • Nemolizumab is a drug showing promise for treating atopic dermatitis (AD) patients, particularly for reducing itching (pruritus).
  • A meta-analysis of six randomized controlled trials found that nemolizumab significantly lowered pruritus and severity of AD compared to placebo, with no major difference in side effects.
  • The study concluded that nemolizumab effectively improves patient quality of life without clear impacts from dosage or duration on itching relief.
View Article and Find Full Text PDF